chr20-63444720-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The ENST00000359125.7(KCNQ2):βc.629G>Aβ(p.Arg210His) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (β β ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R210C) has been classified as Likely pathogenic.
Frequency
Genomes: not found (cov: 33)
Exomes π: 0.0 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
KCNQ2
ENST00000359125.7 missense
ENST00000359125.7 missense
Scores
11
4
4
Clinical Significance
Conservation
PhyloP100: 4.90
Genes affected
KCNQ2 (HGNC:6296): (potassium voltage-gated channel subfamily Q member 2) The M channel is a slowly activating and deactivating potassium channel that plays a critical role in the regulation of neuronal excitability. The M channel is formed by the association of the protein encoded by this gene and a related protein encoded by the KCNQ3 gene, both integral membrane proteins. M channel currents are inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1 (EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 17 ACMG points.
PM1
In a hotspot region, there are 14 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 6 uncertain in ENST00000359125.7
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr20-63444721-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 205873.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), KCNQ2. . Gene score misZ 4.0411 (greater than the threshold 3.09). Trascript score misZ 3.6968 (greater than threshold 3.09). GenCC has associacion of gene with seizures, benign familial neonatal, 1, neonatal-onset developmental and epileptic encephalopathy, benign familial neonatal-infantile seizures, benign neonatal seizures, malignant migrating partial seizures of infancy, neonatal encephalopathy with non-epileptic myoclonus, complex neurodevelopmental disorder, seizures, benign familial neonatal, 2, developmental and epileptic encephalopathy, 7, benign familial infantile epilepsy.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.903
PP5
Variant 20-63444720-C-T is Pathogenic according to our data. Variant chr20-63444720-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 279931.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr20-63444720-C-T is described in Lovd as [Pathogenic]. Variant chr20-63444720-C-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KCNQ2 | NM_172107.4 | c.629G>A | p.Arg210His | missense_variant | 4/17 | ENST00000359125.7 | NP_742105.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KCNQ2 | ENST00000359125.7 | c.629G>A | p.Arg210His | missense_variant | 4/17 | 1 | NM_172107.4 | ENSP00000352035 | A1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1448556Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 719118
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
1448556
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
719118
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10Other:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Developmental and epileptic encephalopathy, 7 Pathogenic:6Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Department Of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University | Jun 30, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital | Oct 20, 2023 | This heterozygous mis-sense variant identified in 1 month female with neonatal onset of seizures from day 1, encephalopathy and abnormal EEG . This variant is absent from gnomAD database [PM2]. Insilico prediction predicts a deleterious nature of this variant, REVEL score: 0.85. Based on the familial segregation is was found to be a βde-novoβ variant. There is a clinvar entry [Variation ID: 279931] for this variant with a Pathogenic interpretation by multiple submitters [PP5]. PMID [26446091] - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | Jul 10, 2019 | The p.Arg210His variant has been reported as a de novo change in multiple individuals with epileptic encephalopathy (PMID: 24107868, 24371303, 25880994, 26446091). It is absent from the ExAC and gnomAD population databases and thus is presumed to be rare. The p.Arg210His variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. This substitution is predicted to be within the transmembrane segment S4 voltage sensor. Functional studies have demonstrated that the p.Arg210His variant disrupts the normal channel conductance activity of the KCNQ2 protein (PMID: 28283543). Analysis of the parental samples was negative for the variant, indicating this variant likely occurred as a de novo event. Based on the available evidence, the c.629G>A (p.Arg210His) variant is classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Pediatric Genetics Clinic, Sheba Medical Center | May 13, 2021 | - - |
not provided, no classification provided | literature only | GeneReviews | - | EE (epileptic encephalopathy) - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital | Jul 17, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Oct 19, 2020 | Based on the classification scheme VCGS_Germline_v1.3.3, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative and loss of function are known mechanisms of disease in this gene and are associated with epileptic encephalopathy, early infantile, 7 (MIM#613720). Missense have been reported with a dominant negative mechanism, causing both early infantile epileptic encephalopathy and benign neonatal seizures (OMIM, PMID 24318194). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity. Some variants have been reported with both severe infantile onset epileptic encephalopathy and milder benign seizures (OMIM) (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to histidine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0603 - Missense variant in a region that is highly intolerant to missense variation (high constraint region in DECIPHER). (SP) 0702 - Other missense variants comparable to the one identified in this case have strong previous evidence for pathogenicity. Alternative changes (p.Arg210Pro, p.Arg210Cys) have been reported in several de novo patients with infantile onset epileptic encephalopathy (ClinVar, PMID: 25818041). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported in multiple de novo patients with infantile onset epileptic encephalopathy (ClinVar, PMID: 24107868, PMID: 24371303, PMID: 26446091). (SP) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed) by trio analysis. (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 13, 2018 | The R210H pathogenic variant has been reported multiple times as a de novo change in individuals with epileptic encephalopathy (Weckhuysen et al., 2013; Pisano et al., 2015; Reid et al., 2016). The R210H variant is not observed in large population cohorts (Lek et al., 2016). The R210H variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. This substitution is predicted to be within the transmembrane segment S4 voltage sensor. In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. In addition, a different missense variant in the same residue (R210C) as well as multiple missense variants in nearby residues have been reported in the Human Gene Mutation Database in association with KCNQ2-related disorders (Stenson et al., 2014), supporting the functional importance of this region of the protein. Therefore, we consider R210H to be a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 23, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2021 | - - |
Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 04, 2023 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 210 of the KCNQ2 protein (p.Arg210His). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with early infantile epileptic encephalopathy (PMID: 24107868, 24371303, 25880994, 26446091). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 279931). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNQ2 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects KCNQ2 function (PMID: 28283543). For these reasons, this variant has been classified as Pathogenic. - |
Complex neurodevelopmental disorder Other:1
not provided, no classification provided | literature only | Channelopathy-Associated Epilepsy Research Center | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
.;.;T;T;D;T;D;T;.;.;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
L;.;.;.;.;.;L;.;L;L;L;.
MutationTaster
Benign
D;D;D;D;D;D;D;D;D;D;D;D
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
.;.;.;.;D;.;D;.;D;D;D;.
REVEL
Pathogenic
Sift
Benign
.;.;.;.;T;.;T;.;T;D;T;.
Sift4G
Benign
T;T;T;T;T;.;T;T;T;T;T;T
Polyphen
D;.;.;.;.;.;D;.;D;D;.;.
Vest4
MutPred
Loss of MoRF binding (P = 0.0537);Loss of MoRF binding (P = 0.0537);Loss of MoRF binding (P = 0.0537);Loss of MoRF binding (P = 0.0537);Loss of MoRF binding (P = 0.0537);.;Loss of MoRF binding (P = 0.0537);.;Loss of MoRF binding (P = 0.0537);Loss of MoRF binding (P = 0.0537);Loss of MoRF binding (P = 0.0537);.;
MVP
MPC
3.1
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at